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Mycobacterium bovis bacille Calmette–Guérin (BCG) is listed as an intralesional (IL)
therapeutic option for inoperable stage III in-transit melanoma in the National Comprehensive
Cancer Network Guidelines. Although the mechanism is unknown, others have reported
up to 50% regression of injected lesions, and 17% regression of uninjected lesions in
immunocompetent patients after direct injection of BCG into metastatic melanoma lesions
in the skin. BCG and other mycobacteria express ligands capable of stimulating the γ9δ2
T cells. Therefore, we hypothesized that γ9δ2 T cells play a role in promoting BCG-mediated
antitumor immunity in patients treated with IL-BCG for in-transit cutaneous melanoma
metastases. Indeed, we found γ9δ2 T cell infiltration in melanoma skin lesions during the
course of IL-BCG treatment. Gene expression analysis revealed that BCG injection elicits
the expression of a vast array of chemokines in tumor lesions, including strong expression
of CXCL9, 10, and 11, a set of chemokines that attract T cells expressing the CXCR3
chemokine receptor. In corroboration with our hypothesis, approximately 85% of γδ T cells
express high levels of CXCR3 on their surface. Importantly, the injected tumor lesions also
express genes whose protein products are the antigenic ligands for γδ T cells (BTN3A1 and
MICB), and the cytokines that are the typical products of activated γδ T cells. Interestingly,
we also found that γδ T cells infiltrate the regressed lesions that did not receive BCG
injections. Our study suggests that γ9δ2 T cells may contribute to melanoma regression
induced by IL-BCG treatment.
Keywords: bacille Calmette–Guérin, melanoma, γδ T cells, immunotherapy, tumor microenvironment

INTRODUCTION
Melanoma is a cutaneous malignancy that kills ~10,000 people annually in the US (1). In contrast to most other types of cancer in which incidences are steadily declining, the incidence of
melanoma continues to climb, especially in young patients (1). Melanoma treatment has been strikingly improved through the use of immune-based approaches (2–4), emphasizing the significant
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protective role of immune cells against melanoma. Intralesional
(IL) Mycobacterium bovis bacille Calmette–Guérin (BCG), or
IL-BCG, is currently a recommended therapy in the National
Comprehensive Cancer Network (NCCN) Guidelines (version
1.2017) for inoperable stage III in-transit metastatic melanoma.
Direct injection of BCG into metastatic melanoma lesions in
the skin has resulted in up to 90% regression of injected lesions
and 17% regression of uninjected lesions in immunocompetent
patients (5, 6). Epidermal injection of BCG induces a typical
delayed hypersensitivity response, characterized by numerous
chemokines and cytokines and recruitment of a vast array of
immune cells into the BCG injected sites (7). It is well accepted
that the immune response plays an important role in IL-BCGinduced tumor regression.
Mycobacterial infection recruits γδ T cells to the infected
lymph nodes during early stages of infection (8). This rapid res
ponse by γδ T cells is an important factor in the host control
of the mycobacterial infection (9, 10). γδ T cells are a subset of
T cells making up 1–5% of the total CD3+ T cells in peripheral
blood (11, 12). Unlike αβ TCR lineage, γδ T cells usually do not
express CD4 or CD8, but only CD3 (11, 13), and direct TCR
signaling through the associated CD3 complex (14). γδ T cell
antigen recognition does not require conventional antigen
presentation in the context of MHC (15), and they may recognize unconventional antigens including stress molecules like
MICA and MICB and non-peptide metabolites of isoprenoid
biosynthesis (16–19). Human γδ T cells can be divided into three
main populations based on their δ chain expression: Vδ1, Vδ2,
and Vδ3. γδ T cells expressing Vδ2 chain represent the majority
of circulating γδ T cells in healthy human adults, comprising
50–90% of the peripheral γδ T cell population. The Vδ2 chain
pairs almost exclusively with Vγ9. Stimulation of PBMCs with
BCG induces the preferential expansion of the γ9δ2 subset
(20, 21). This subset of γδ T cells recognizes small non-peptidic
phosphorylated antigens, such as microbial hydroxymethyl-but2-enyl-pyrophosphate (HMBPP) produced by infectious agents
and recognized as non-self, and induces the production of host
phosphoantigens, such as isopentenyl pyrophosphate (IPP), the
intermediates of isoprenoid biosynthesis of mevalonate pathway, accumulated in infected or transformed cells (19, 22–25).
Mycobacteria can produce HMBPP and stimulate host cells to
produce IPP (18). Tumor cells themselves can also express IPP
to the levels sufficient to activate Vδ2 T cells (26, 27) due to the
dysfunctional mevalonate pathway in tumors (28). Therefore,
γδ T cells not only participate in the control of mycobacterial
infections but have also displayed a broad cytotoxicity against a
wide variety of tumor types, including leukemia, neuroblastoma,
melanoma, and various carcinomas (29–33). Besides their direct
tumoricidal activity, activated γδ T cells also display antigenpresenting cell properties characterized by the expression of high
levels of HLA-DR and costimulatory molecules such as CD80 and
CD86 (34, 35) that could support adaptive immune responses
(36). With all these properties, γδ T cells have been considered
and evaluated as adoptive immunotherapeutic cells for tumor
immunotherapy (37–39).
In this study, we investigate whether γδ T cells play a role in
IL-BCG-induced melanoma regressions.

Frontiers in Oncology | www.frontiersin.org

Patients and IL-BCG Treatment

Between 2011 and 2013, eight patients studied were diagnosed
with stage III in-transit melanoma and treated with IL-BCG
according to the NCCN guidelines. Patient information was
obtained retrospectively from a single, high volume melanoma
referral center following internal review board (IRB) approval.
The goal of treatment was local control and palliation or prevention of symptoms associated with in-transit disease. Following
a negative tuberculin skin test result, patients were sensitized to
BCG at distant sites with intradermal injections of BCG to sites
adjacent to regional nodal basins initially. Following sensitization,
if applicable, patients then received intradermal BCG injections
in the target in-transit lesions, typically 2 weeks later. IL injection
doses following sensitization were typically lower and titrated
to produce a moderate local inflammatory response to avoid
skin necrosis and the development of vesicles. These in-transit
metastases were injected no more frequently than every 2 weeks.
IL-BCG administration was continued until complete resolution
or disease progression. The use of patient and healthy donor
samples was reviewed and approved by Alpha IRB in this study.

Immunohistochemistry

The melanoma specimens were obtained by surgical resection
or open biopsy. Frozen melanoma sections (5-µm thick) were
fixed in pre-cooled acetone and rinsed with phosphate buffered
saline at a neutral pH. The tissue sections were blocked with
normal horse serum. Properly diluted 100 µL of anti-CD3
(F7.2.38, Dako), γδ TCR (IMMU510, Fisher Scientific), Vγ9
TCR (7A5, Fisher Scientific), or isotype control antibodies were
applied on tissue sections. Anti-mouse IgG–HRP conjugate
was used as a secondary antibody to develop the AEC color of
specific staining.

RNA Isolation, cDNA Preparation, and
RNA Sequencing (RNAseq)

Bacille Calmette–Guérin injected and uninjected melanoma
biopsies from IL-BCG-treated patients were minced into small
pieces. Total RNA from both sources was extracted using the
Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). cDNA
libraries were prepared using TruSeq RNA Library Preparation
Kit v2 (RS-122-2001) according to the “TruSeq RNA Sample
Preparation v2 Guide” (Illumina, San Diego, CA, USA). Briefly,
poly-A+ mRNA was isolated from 300 ng total RNA using
polyoligo-dT attached on magnetic beads. After fragmentation
with divalent cations under elevated temperature, the cleaved
RNA fragments were transcribed into first-strand cDNA using
reverse transcriptase and random primers. Second-strand cDNA
was synthesized using DNA polymerase I and RNase H. These
cDNA fragments were end-repaired, added with single “A” base,
and ligated with adapters. The products were then purified and
enriched with PCR to create the final cDNA library. Libraries
were sequenced on Illumina HiSeq2000 at 50 million reads per
sample and 1 × 50 read length. These procedures were performed
by the UCLA Clinical Microarray Core facility.
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RNAseq Data Processing and Analysis

For the RNAseq gene expression analysis, immune-related
genes and housekeeping genes were preselected to reduce false
discovery rate from multiple hypothesis testing. The differential expression between BCG injected (n = 9) and uninjected
(n = 10) was tested using the non-parametric two-sided Mann–
Whitney test. False discovery rate was controlled for by applying
Benjamini–Hochberg adjustment to resulting p-values. Genes
meeting the 5% alpha threshold were considered to be statistically significant. Statistics were performed on R version 3.3.1 and
plots generated using ggplot2_2.2.0 package.

The reads obtained by RNAseq were processed and analyzed with
specific tools piped together using Ubuntu. Quality assurance
of reads (GC content, adaptors, and PHRED score assessment)
were done with FastQC. Trimming to remove poor quality reads
and adapters was performed using Trimmomatic. The reads were
scanned with a four base wide sliding window and cut when
average quality dropped below 15 phred score. Reads less than 36
bases long were removed. Read-mapping to the human reference
genome hg19 and abundance estimation of genes and isoforms
was done using Bowtie2 aligner within RSEM with default values
(40). We compared the RSEM normalized RPKM/FPKM values
of chemokine receptors, cytokines, butyrophilin subfamily 3
member A1 (BTN3A1), and MHC class-I polypeptide-related
sequence A and B (MICA and MICB). Vγ9 was quantitated by the
basic local alignment search tool using a fasta reference downloaded from the NCBI database. The Vγ9 counts were normalized
into counts per million.

RESULTS
IL-BCG Induces Melanoma Regression
Accompanied by γδ T Cell Infiltration

In this study, eight in-transit stage III melanoma patients were
treated with IL-BCG as described in the Section “Materials
and Methods.” As expected, BCG injection induced complete
or partial regression of injected melanoma lesions in six of
eight patients (Figure 1A). The details of patients’ response to
therapy are summarized in Table S1 in Supplementary Material.
Immunohistological analysis revealed that while CD3 cell infiltration occurs in both IL-BCG-treated and non-treated lesions, γδ
T cell infiltration was observed only in the IL-BCG-treated lesions
(Figure 1B). Some of these infiltrated cells are Vγ9-expressing
cells (Figure 1B). To verify that an influx of γδ T cells occurred
with IL-BCG injection, the total RNA samples isolated from these
lesions were subjected to the high-throughput RNAseq analysis.
In agreement with the above finding, the Vγ9 gene expression was
significantly higher in the IL-BCG-treated lesions (Figure 1C)
according to RNAseq analysis. There were no differences in the
expression of housekeeping genes such as ER membrane protein
complex subunit 7 (EMC7), charged multivesicular body protein
2A (CHMP2A), and chromosome 1 open reading frame 43
(C1orf43) (Figure 1C and data not shown) (41).

T Cell Composition and Phenotype
Analysis of PBMCs

Frozen PBMCs (0.2–0.5 × 106/tube) from healthy donors were
stained with anti-CD3 (APC-H7, BD Biosciences), anti-αβ TCR
(FITC, BioLegend), and anti-γδ TCR (APC), along with additional
antibodies, Vγ9 TCR (PE), CXCR3 (CD183) (PE), CCR4 (CD194)
(PerCP-Cy5.5), CCR6 (CD196) (PerCP-Cy5.5), and CLA (PE).
The phenotypes of cells were analyzed on BD FACSVerse.
To study the effect of BCG stimulation on the expansion of γδ
T cells, frozen PBMCs (2.5 × 106/mL/well in a 48-well plate) from
healthy donors were suspended in T cell culture medium (RPMI1640, containing 10% human serum, 1% sodium pyruvate, 1%
penicillin/streptomycin; Invitrogen, Carlsbad, CA, USA), stimulated with or without BCG live vaccine (TICE BCG University of
Illinois, IL, USA) at final concentration of 105 colony-forming units/
milliliter. After 6 days in culture at 7% CO2, 37°C, the cells were
stained with anti-CD3 (APC-H7), anti-γδ TCR (APC), along with
one of the following additional antibodies: anti-αβ TCR (FITC),
HLA-DR (FITC), or Vγ9 TCR (PE). The phenotypes of cells were
analyzed on BD FACSVerse.

IL-BCG Induces Chemokines That Attract
CXCR3-Expressing T Cells; γδ T Cells Are
Predominantly CXCR3-Expressing Cells

Isolation and Composition Analysis of
Tumor Infiltrated Lymphocytes (TILs)

Intralesional injection of BCG induces a massive secretion of
chemokines and cytokines that recruit immune cells (7). We interrogated whether IL-BCG treatment induces chemokines responsible for attracting γδ T cells to injection sites using RNAseq. We
found that many chemokines were significantly upregulated in
the IL-BCG-treated tumors (Table 1). Among them, chemokines
CXCL9, CXCL10, CXCL11 for CXCR3 (CD183), and CCL20 for
CCR6 (CD196) receptors were all upregulated (Figure 2A; Figure
S1A and Table S1 in Supplementary Material). Chemokines
CXCL9, CXCL10, and CXCL11 for CXCR3 receptor showed
the highest fold changes (approximately 10-fold) and absolute
increase in gene expression (Figure 2A; Table 1). Corroborating
that finding, most γδ T cells from PBMCs express high levels
of CXCR3 receptors on their surfaces (Figure 2B), while very
few γδ T cells express CCR4 or CCR6 receptors (Figures S1B,C
in Supplementary Material). These data suggest that IL-BCG

Biopsies of regressed and non-regressed melanoma tissue were
sterilely minced into pieces 1–2 mm in diameter. The minced
tissue specimens were then attached to the cell foam matrices
pre-coated with collagen to resemble 3D culture. The tumor
specimens were cultured in 2 mL of skin T cell medium (Iscove’s
medium containing 10% fetal bovine serum, 100 U/mL IL-2, and
10 ng/mL of IL-15) in a 24-well plate. The medium was replaced
with half of fresh skin T cell medium every other day. After 21 days
of culture, T cells that migrated out of the melanoma tissue were
collected. Lymphocyte composition of TILs was analyzed with
anti-γδ and αβ TCR antibodies by flow cytometry.

Statistical Analysis

For T cell composition and phenotype analyses by flow cytometry,
paired Student’s t-test was used as indicated in the figure captions.
Frontiers in Oncology | www.frontiersin.org
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Figure 1 | IL-BCG-induced tumor regression is associated with the presence of γδ T cells. (A) IL-BCG induces tumor regression. Scale bars represent
1 cm. (B) Presence of γ9 γδ T cells in IL-BCG-injected tumors. Scale bars represent 100 µm. (C) Increased mRNA expression of Vγ9 transcripts in the injected
tumor tissue by RNA sequencing [fragments per kilobase of exon per million fragments mapped (FPKM)]. EMC7 is a representative housekeeping gene control (41).

treatment could attract γδ T cells to the injection sites through
the CXCL9/10/11–CXCR3 chemotaxis axis. Consistent with the
attraction of γδ T cells, IL-BCG also elicits a significant elevation
of signature cytokines from γδ T cells, including IFNγ (42, 43),
TNFα, TNFβ, and IL-15 (44) (Figure 2C; Table 2).

chain-related molecules, MICA and MICB (45). To investigate
whether IL-BCG injection induces these γδ T cell targets, we compared the RNA expression profiles between IL-BCG non-injected
and injected lesions. IL-BCG injection induced the elevated
expression of both BTN3A1 and MICB molecules (Figure 3A).
To examine whether BCG could activate and expand γδ
T cells, we stimulated the PBMCs with live BCG. After 6 days
of in vitro stimulation, γδ T cells were significantly expanded
in the cultures treated with BCG, but not in the wells without
BCG (Figure 3A). The newly expanded γδ T cells expressed a
high level of HLA-DR, an activation marker for T cells after they
respond to the cognate antigen stimulation (Figure 3D, solid
line). Little or no HLA-DR expression was seen on γδ T cells in
the well without BCG (Figure 3D, shaded area). Also, little or no
HLA-DR expression was seen on αβ T cells from the well treated
with BCG (Figure 3D, dashed line). The expanded cells were

IL-BCG Upregulates Local Expression of
Molecules That May Present Antigens
to γδ T Cells, and BCG Stimulation
Preferentially Activates and Expands
Vγ9 T Cells

Unlike αβ T cells that recognize peptide fragments restricted on
MHC molecules, γδ T cells recognize unconventional antigens
such as normal cellular metabolites of IPP presented on BTN3A1
(CD277) molecules (19, 22) or the stress-induced MHC class-I

Frontiers in Oncology | www.frontiersin.org
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Table 1 | Expression levels (FPKM) of chemokines in bacille Calmette–Guérin injected and uninjected melanoma tissue.
Chemokine
CCL1
CCL2
CCL3
CCL3L1
CCL3L3
CCL4
CCL4L1
CCL4L2
CCL5
CCL7
CCL8
CCL11
CCL13
CCL14
CCL15
CCL15–CCL14
CCL16
CCL17
CCL18
CCL19
CCL20
CCL21
CCL22
CCL23
CCL24
CCL25
CCL26
CCL27
CCL28
CXCL1
CXCL2
CXCL3
CXCL5
CXCL6
CXCL8
CXCL9
CXCL10
CXCL11
CXCL12
CXCL13
CXCL14
CXCL16
CXCL17

avg.Uninj (10)

avg.Inj (9)

p.value

p.adjusted

0
40.8
12.4
1.8
1.7
13.1
2.2
3.1
26.7
0.1
1.9
0.1
13.3
15.2
0.1
0.1
1.2
1.1
54.5
17
0.3
17.5
5.9
0.8
0
0
0.9
49.2
4.5
3.3
1.9
0.1
0
0
0.9
48.8
41.6
3.7
110.6
1
446.4
14.7
0.1

0.7
157.1
75.7
9.6
8.9
109.9
28.4
36
73.3
3.1
22.4
2.6
24.4
16.5
2
0.3
1.1
2.2
520
56.6
1.5
53.6
12.9
2.9
0.1
0
0.7
17
2.8
49.4
4.9
0.7
31.6
1.9
28.2
475.3
404.3
43.8
121.7
15.1
158.1
41.1
1.1

--0.000
0.001
0.082
0.064
0.000
0.001
0.001
0.003
0.002
0.000
0.002
0.113
0.447
0.002
--0.595
0.111
0.000
0.017
0.009
0.006
0.079
0.016
----0.713
0.156
0.102
0.001
0.002
0.040
0.000
0.025
0.001
0.000
0.001
0.000
0.720
0.009
0.113
0.001
0.052

--0.000
0.005
0.125
0.101
0.001
0.003
0.004
0.008
0.005
0.000
0.006
0.159
0.514
0.007
--0.656
0.159
0.001
0.032
0.021
0.014
0.122
0.030
----0.767
0.204
0.151
0.003
0.006
0.068
0.002
0.044
0.004
0.002
0.003
0.001
0.767
0.019
0.159
0.003
0.084

Significance

***
**

***
**
**
**
**
***
**

**

***
*
*
*
*

**
**
**
*
**
**
**
***
*
**

Differential expression between injected (n = 9) and uninjected (n = 10) were tested using a non-parametric two-sided Mann–Whitney test. Genes were considered significant at the
5% alpha threshold. Multiple hypothesis testing was accounted for using Benjamini–Hochberg false discovery correction.
Avg.Uninj, average uninjected; Avg.Inj, average injected; p.value, Mann–Whitney test p-value; p.adjusted, Benjamini–Hochberg adjusted p-value.
Significance: *, <0.005; **, <0.01; ***, <0.001.
---, gene was not evaluated because average FPKM levels across samples were less than 0.25.

with BCG (Figure 4A). After 21 days of culture in the presence
of IL-2 and IL-15, the composition of TILs from regressed
and non-regressed tissues was analyzed via flow cytometry.
Figure 4B shows a clear population of γδ T cells in the TILs from
the regressed melanoma tissue. Interestingly, 72.3% of these γδ
T cells from regressed melanoma specimens express IFNγ in this
mixed culture of tumor and TILs without additional stimulation
(Figure 4C). No such population of γδ T cells was found in TILs
from adjacent non-regressed melanoma tissue (Figure 4C).
Similar analysis was performed on the αβ T cell population. αβ
T cells from both regressed and non-regressed tissues secreted
minimal levels (0.07 and 0.12%, respectively) of IFNγ (Figure S2

predominantly Vγ9-expressing cells (Figures 3B,C). Together,
these data suggest that BCG preferentially activates γδ T cells,
specifically, Vγ9-expressing cells.

γδ T Cells Infiltrate Uninjected Regressed
Tumor Lesions

IL-BCG treatment not only induces the regression of injected
tumors but also occasionally induces the regression of uninjected
tumors (Figure 4A) (5, 6). To investigate whether γδ T cells also
participate in the regression of non-injected in-transit lesions
during IL-BCG treatment, we compared TILs from regressed and
non-regressed tumors. Both lesions studied had not been injected

Frontiers in Oncology | www.frontiersin.org
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Figure 2 | IL-BCG induces secretion of chemokines that attract γδ T cells. (A) Elevation of chemokines that attract CXCR3 expression cells. ***, Student’s
t-test, p < 0.001. (B) γδ T cells express high levels of CXCR3. Right panel: percentage of γδ and αβ T cells among CD3+ T cells from a representative donor. Middle
panel: histogram of FACS staining of CXCR3 on γδ T cells (solid line) and αβ T cells (dashed line). Right panel: summary of % of CXCR3+ T cells in αβ T cells and γδ
T cells, respectively. **, paired t-test, p < 0.01. (C) Elevation of cytokines that can be contributed from activated γδ T cells.

it is likely that adjuvant therapy with BCG induces multilayer
antitumor activities. Discovering what is behind these antitumor
activities is essential to optimizing the therapeutic effects of
adjuvant BCG therapy. Few studies have focused on the role
played by γδ T cells in BCG-induced antitumor activity (35). γδ
T cells comprise a small proportion of T cells that have limited
T cell receptor diversity and unconventional, MHC-independent,
antigen-recognition mechanisms. The role of γδ T cells in tumor
immunology has not been fully appreciated when compared
to αβ T cells. Here, we found that IL-BCG treatment induces
a response that has the capacity to actively attract γδ T cells,
selectively expand Vγ9 T cells, and upregulate antigens recognized by Vγ9Vδ2 T cells in injected lesions. These data suggest
that γδ T cells are strongly associated with the antitumor activity
induced by IL-BCG. Furthermore, γδ T cells are also present in
regressed lesions that are not injected with BCG. This association
suggests a primary role of γδ T cells in the induction of melanoma
regressions (48).
It has been reported that γδ T cells play a critical role in the
control of mycobacterial infections in both humans and animals

in Supplementary Material). These data suggest that IFNγ from
γδ T cells may contribute to tumor regression by IL-BCG.

DISCUSSION
Bacille Calmette–Guérin has been widely used as an immunotherapeutic adjuvant for over 30 years (5, 6). Currently, it is a
recommended agent for the treatment of bladder cancer and
melanoma in the NCCN guidelines. Despite this, the mechanisms
of BCG responses are poorly understood. Previous studies have
revealed that multiple cellular components and soluble factors
contribute to the BCG-induced antitumor activity of bladder cancer (7), including T cells, natural killer cells, macrophages, dendritic
cells, and even granulocytes, as well as the soluble factors released
from these cells. In clinical trials, immune competence is also a
prerequisite of BCG-induced antitumor activity in melanoma
(5, 6). Animal studies highlight that CD4 and CD8 T cells, in
addition to NK cells, played indispensable roles (7). Lack of these
cells abolished BCG-induced antitumor activity of BCG vaccination in bladder cancer in animal models (7, 46, 47). Therefore,

Frontiers in Oncology | www.frontiersin.org
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Table 2 | Expression levels of cytokines in bacille Calmette–Guérin injected and uninjected melanoma tissues.
Cytokine name
GMCSF
IFNα
IFNβ
IFNγ
IL-1A
IL-1B
IL-1F10
IL-2
IL-3
IL-4
IL-5
IL-6
IL-6ST
IL-7
IL-8 (CCL8)
IL-9
IL-10
IL-11
IL-12B
IL-13
IL-14
IL-15
IL-16
IL-17A
IL-17B
IL-17C
IL-17D
IL-17F
IL-18
IL-18BP
IL-19
IL-20
IL-21
IL-21-AS1
IL-22
IL-23A
IL-24
IL-25
IL-26
IL-27
IL-28
IL-29
IL-31
IL-32
IL-33
IL-34
IL-36A
IL-36B
IL-36G
IL-37
TGFβ1
TGFβ2
TGFβ3
TNFα
TNFβ

avg.Uninj (10)

avg.Inj (9)

p.value

p.adjusted

Significance

0.2
0
0
0.9
0.2
1
1
0
0.1
0.1
0
1.1
32.1
1.6
1.9
0.1
1.8
0.3
0.1
0.1
15.1
2
7.6
0
0.1
0
6.9
0
39.4
12.2
0
0
0
0
0
0.1
0.1
0
0.1
0
0
0.1
0
9.4
7.8
4
0
1
4.3
14.9
2.9
7
6
2.2
0.2

1
0
0
7.4
1.9
82.7
0.3
0.2
0
0
0.1
20.2
36.2
2.6
22.4
0.1
3.5
0.3
0.4
0.1
15.2
8.9
6.1
0
0.3
0
0.8
0
42.1
45.5
0.1
0.5
0.1
0.1
0.1
0.8
2
0
0.7
0.2
0
0
0
52.7
13.1
1.5
0.1
1
3.1
2.1
5.8
1.5
11.8
9.2
1.3

0.019
----0.004
0.002
0.000
0.281
--------0.002
0.400
0.050
0.000
--0.006
0.713
0.016
--0.968
0.000
0.133
------0.002
--0.400
0.001
----------0.007
0.014
--0.001
--------0.000
0.243
0.315
--0.902
0.967
0.108
0.004
0.065
0.028
0.000
0.001

0.035
----0.011
0.006
0.001
0.353
--------0.006
0.466
0.082
0.000
--0.014
0.767
0.030
--0.974
0.002
0.177
------0.006
--0.466
0.003
----------0.016
0.027
--0.004
--------0.001
0.310
0.387
--0.919
0.974
0.158
0.011
0.103
0.048
0.000
0.004

*

*
**
***

**
*
***
*
*

**

**

**

*
*
**

***

*
*
***
**

Differential expression between injected (n = 9) and uninjected (n = 10) were tested using a non-parametric two-sided Mann–Whitney test. Genes were considered significant at the
5% alpha threshold. Multiple hypothesis testing was accounted for using Benjamini–Hochberg false discovery correction.
Avg.Uninj, average uninjected; Avg.Inj, average injected; p.value, Mann–Whitney test p-value; p.adjusted, Benjamini–Hochberg adjusted p-value.
Significance: *, <0.005; **, <0.01; ***, <0.001.
---, gene was not evaluated because average FPKM levels across samples were less than 0.25.

(49, 50). Primary M. bovis BCG infection induces major clonal
expansion of phosphoantigen-specific Vγ2Vδ2 (also termed as
Vγ9Vδ2) T cells (51, 52). In this study, we confirmed that BCG
preferentially activates and expands Vγ9 γδ T cells in PBMC
Frontiers in Oncology | www.frontiersin.org

in vitro, with more than a 20-fold expansion in 6-day stimulation
from frozen PBMCs (Figure 3B). Meanwhile, very few CD3+
αβ T cells were activated and expanded from these PBMCs
(Figure 3D). This rapid, preferential activation of Vγ9 γδ T cells
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Figure 3 | Continued
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Figure 3 | Continued
IL-BCG injection induces the elevated expression of target antigens for γδ T cells, bacille Calmette–Guérin (BCG) stimulation preferentially activates
and expands γ9δ2 T cells. (A) IL-BCG induces the elevated expression of antigens for γδ T cells. (B) BCG stimulation expands γδ T cells preferentially. Left panel:
histogram of FACS staining on γδ T cells without BCG stimulation for 6 days. Middle panel: histogram of FACS staining on γδ T cells with BCG stimulation for
6 days. Right panel: summary of percentage of γδ+ T cells without or with BCG stimulation for 6 days. **, paired t-test, p < 0.01. (C) BCG expanded γδ T cells are
predominantly Vγ9+ cells. Left panel: a representative histogram of FACS staining on Vγ9. Right panel: summary of percentage of Vγ9+ cells in γδ T cells treated
with or without BCG. *, paired t-test, p < 0.05. (D) BCG preferentially activates γδ T cells, not αβ T cells. Left panel: a representative histogram of FACS staining on
HLA-DR. Right panel: summary of percentage of HLA-DR+ cells for γδ T cells with or without BCG stimulation and αβ T cells with BCG stimulation. ***, paired t-test,
p < 0.001; ****, paired t-test, p < 0.0001.

Figure 4 | IL-BCG induces tumor regressions in uninjected melanoma lesions. (A) IL-BCG induces regression of uninjected lesions. Upper left: in-transit
melanoma metastases at the time of first IL-BCG treatment. Upper middle: 8 weeks post-IL-BCG, tumors exhibit mild to moderate inflammation. Upper right:
13 weeks post-IL-BCG. Adjacent uninjected tumors (white arrows) exhibiting regression (R) or non-regression (NR). (B) Presence of γδ T cells in regressed but not
non-regressed uninjected melanoma lesions. (C) IFNγ secretion of tumor infiltrated by γδ T cells. Tumors infiltrated by γδ T cells secrete IFNγ isolated from regressed
but not non-regressed uninjected melanoma lesions.

is not only consistent with the role γδ T cells play in the early
control of mycobacterial infections (9, 10) but also provides a
mechanism by which Vγ9Vδ2 T cells could impact antitumor
activity (38, 48).
Frontiers in Oncology | www.frontiersin.org

Target antigens for Vγ9Vδ2 T cells are phosphoantigens, the
low molecular weight metabolites of the mevalonate pathway
(19, 22). Infection and physiologic stress can cause dysregulation
of the mevalonate pathway and induce elevated phosphoantigen
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metabolism. Meanwhile, infection and stress also induce
expression of the BTN3A family of molecules, putative molecules
that present phosphoantigens to Vγ9Vδ2 T cells (22). It is not surprising, therefore, that IL-BCG treatment can induce melanoma
regression at injected sites, and that these regressions are strongly
associated with the presence of Vγ9Vδ2 T cells (48). Besides
infection, tumors are stressed due to rapid growth, limited oxygen and nutrient supplies. These physiologic stressors also induce
dysregulation of the mevalonate pathway and expression of
BTN3A proteins (22). Since BCG preferentially activates and
expands Vγ9Vδ2 T cells in a locoregional manner, it is perceivable that some Vγ9Vδ2 T cells could migrate to the stressed
tumor itself and execute antitumor activity in non-injected
lesions. In addition to mediating the expression of BTN3A for
γδ T cell response, BCG therapy also enhances the expression
of MIC B in injected tumor lesions (Figure 3A), another target
Ag for γδ T cells and NK T cells (7). The main point of our study
was to investigate the role of γδ T cells on the activity induced by
IL-BCG treatment but was not intended to exclude the potential
role of other cells. We cannot rule out that NK cells may also
contribute to the observed regression, and future studies are
warranted to determine the mechanism of regression to answer
whether γδ T cells actively lyse the tumors or influence the tumor
cells to limit growth in other ways. Since NK cells are known to
have these capabilities, their potential role in BCG cannot be
ruled out.
Bacille Calmette–Guérin infection or vaccination induces
strong delayed type hypersensitivity responses (7), a typical Th1
type response. This response recruits diversified inflammatory
cells and stimulates the release of a variety of cytokines and
chemokines. IL-BCG treatment induces a long-lasting highlevel release of chemokines such as CXCL9, 10, and 11, a set of
chemokines that recruit CXCR3 expression cells. Interestingly,
90% of γδ T cells in the peripheral blood express high levels of
CXCR3 receptors. This observation further supports the conclusion that IL-BCG can recruit γδ T cells to the injected lesions
and expand the Vγ9Vδ2 T cell subset. This observation further
supports the conclusion that IL-BCG can recruit γδ T cells to the
injected lesions and expand the Vγ9Vδ2 T cell subset.
Cytokines are the mediators of immune cells that execute the
activity of immune responses. Among the long list of cytokines
expressed at BCG-injected tumor lesions (Table 2), the expression of several cytokines, IFNγ (42, 43), IL-15 (44), and TNFα,
accompany the increase in γδ T cells. These cytokines can
have direct and indirect antitumor activities during immune
responses (7). Therefore, expression of these cytokines (despite
the fact that they are not unique for γδ T cells and can be
expressed by NK cells and other αβ T helper cells) also corroborates the hypothesized positive role of γδ T cells in BCGinduced antitumor activity. Alternately, BCG is live vaccine
that can induce strong cellular immune responses. As negative
feedback of these immune responses, it is expected that BCG
injection will induce the expression of regulatory factors, such
as immunosuppressive cytokines that can downregulate antitumor activity. IL-17 is a product of regulatory γδ T cells during
the early phase of immune response (53, 54). IL-17-producing
regulatory γδ T cells have been shown to mediate pro-tumor
Frontiers in Oncology | www.frontiersin.org

activities in mouse models (53, 54). Interestingly, the expression of IL-17 (only IL-17D isoform) is clearly downregulated in
BCG-injected melanoma lesions (Table 2). It is possible that
the time of sample collection is out of IL-17 expression phase,
or BCG recruited γ9δ2 subset is effector γδ T cells (53–55).
Nevertheless, this observation also supports the notion of a
positive role of γδ T cells in BCG-induced antitumor activity. However, BCG injection does induce the expression of
cytokines that play pro-tumor activities, including IL-1β, 6,
8, 10, 18BP (56), 26, 32 (57), and TGFβ (58, 59) (Table 2).
Whether all or part of these cytokines are produced by γδ
T cells in BCG-injected lesions is unknown. This will be an
important topic for the future study to improve the efficacy
of BCG therapy, since BCG therapy does not always eradicate
melanoma completely.
IL-BCG therapy can induce regression of injected and uninjected melanoma lesions, but durable clinical responses are not
observed in all treated patients. The limited effect of this treatment
may be due to the transient nature of the inflammatory response
induced. We found the highest expression of chemokines and
cytokines in BCG-treated melanoma skin metastases 4 weeks
after IL-BCG injection are CCL2 (40.8 vs. 157.1, of the average
FPKM in BCG uninjected vs. BCG injected melanoma tissues),
CCL3 (12.4 vs. 75.7), CCL4 (13.1 vs. 109.9), CCL5 (26.7 vs. 73.3),
CCL18 (54.5 vs. 520), CXCL9 (48.8 vs. 475.3), and CXCL10
(41.6 vs. 404.3) (Table 1). These chemokines are usually released
from the monocyte/macrophage lineage and mast cells during
the acute phase of the inflammatory immune response (60, 61).
High-level expression of these chemokines not only recruits
and activates type 1 macrophages and neutrophils (60) but also
recruits immune regulatory cells such as T regulatory cells through
CCL2, CCL18 chemotaxis (60, 62, 63), myeloid-derived suppressor cells (60, 62, 63), and type 2 neutrophils (60, 64) through
CCL2, CCL3, CCL4, and CCL5 chemotaxis. These immunosuppressive cells may counter any antitumor immune responses. On
the other hand, high-level expression of CXCL9 and CXCL10
recruit Th1 CD4 cells, cytotoxic CD8 T cells, NK cells, and γδ
T cells, through the CXCL9 and CXCL10/CXCR3 chemotactic
axis (60). Activation of these cells can stimulate IFNγ, IL-6, IL-8,
IL-10, IL-15, IL-18BP, IL-32, TGFβ1, TGFβ3, and TNFα release
as the average FKPMs of most of cytokines are below 10 (Table 2)
in contrast to 100–500 for the chemokines (Table 1). Whatever
the source, a substantial number of cytokines induced by IL-BCG
favor the tumor, such as IL-1β (65), IL-6 (66), IL-8 (67), IL-10,
IL-18BP (65), IL-32 (57, 68), and TGFβ (55, 56). Even TNFα and
IFNγ may have dual effects. For example, at high concentrations,
TNFα can kill sarcoma cells by binding to the TNFR1 and inducing apoptosis (58). In contrast, at sustained low levels, TNFα
promotes tumorigenesis by inducing the generation of reactive
oxygen and nitrogen species to induce DNA damage (58). IFNγ
can activate cytotoxic T cells and macrophages to kill tumor cells;
meanwhile, persistent expression of IFNγ can induce expression
of immune checkpoint molecules such as PD-L1 on tumor cells
and antigen-presenting cells to diminish T cell antitumor activities (69). How the combination of cytokines, chemokines, and
the cells they recruit to the local tumor microenvironment lead
to tumor progression or regression has yet to be understood and
10
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likely depends on numerous factors that vary from individual
to individual. BCG, as an attenuated live vaccine, is an excellent
biological agent to investigate the effect of local inflammation on
antitumor activity. Our studies indicate γδ T cells may play an
important role in this process.
In summary, our study suggests an association of Vγ9Vδ2
T cells with IL-BCG-induced melanoma regressions, consistent
with the latest clinical discovery that the frequency of Vδ2+
γδ T cells is positively correlated with overall survival in melanoma patients treated with ipilimumab (48). Analysis of gene
expression profiles induces type 1 immunity and may promote
a unique Vγ9Vδ2 T cell infiltration profile. Further study of
these immunological profiles will provide valuable insight in the
search for novel checkpoint targets and for the development of
novel combinations of BCG therapy and checkpoint inhibition
in melanoma and bladder cancer.
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